HC Wainwright Boosts Earnings Estimates for Cassava Sciences

Cassava Sciences, Inc. (NASDAQ:SAVA) – HC Wainwright increased their FY2025 earnings per share estimates for Cassava Sciences in a research note issued on Tuesday, March 4th. HC Wainwright analyst V. Bernardino now expects that the company will post earnings per share of ($0.55) for the year, up from their prior forecast of ($0.62). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Cassava Sciences’ current full-year earnings is ($3.97) per share.

Cassava Sciences Trading Down 0.4 %

SAVA opened at $2.81 on Friday. The stock has a fifty day simple moving average of $2.56 and a two-hundred day simple moving average of $14.76. The company has a market cap of $135.19 million, a price-to-earnings ratio of -2.04 and a beta of -1.24. Cassava Sciences has a 12-month low of $2.23 and a 12-month high of $42.20.

Cassava Sciences (NASDAQ:SAVA) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($0.57) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.11.

Hedge Funds Weigh In On Cassava Sciences

Institutional investors have recently added to or reduced their stakes in the company. Sequoia Financial Advisors LLC bought a new position in Cassava Sciences in the fourth quarter worth $26,000. CANADA LIFE ASSURANCE Co raised its holdings in Cassava Sciences by 198.4% in the fourth quarter. CANADA LIFE ASSURANCE Co now owns 11,380 shares of the company’s stock worth $27,000 after purchasing an additional 7,566 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new position in Cassava Sciences in the fourth quarter worth $27,000. Johnson Investment Counsel Inc. raised its holdings in Cassava Sciences by 71.4% in the fourth quarter. Johnson Investment Counsel Inc. now owns 12,000 shares of the company’s stock worth $28,000 after purchasing an additional 5,000 shares in the last quarter. Finally, Catalina Capital Group LLC bought a new position in Cassava Sciences in the fourth quarter worth $32,000. Institutional investors own 38.05% of the company’s stock.

About Cassava Sciences

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.